KURA reports tumor shrinkage in 77% of patients in drug combination trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
May 26, 2026 6:02 AM EDTTumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients
ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients
Results reinforce darlifarnibs potential as a precision combination agent across targeted therapies
Clear clinical activity in KRASi-experienced patients and manageable safety profile
Virtual investor event on June 3, 2026, at 12:15 p.m. PT / 3:15 p.m. ETÂ
SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for... More
